ATS View
한국어

Orum Therapeutics KRX:475830KOSDAQ

오름테라퓨틱 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days3
DART filings, 7 days4
Articles tracked60since Sep 11

In Q2 2026, Orum Therapeutics reported revenue of ₩24m, up 479.1% year on year, and an operating loss of ₩15.4bn. Orum Therapeutics (오름테라퓨틱) appeared in 3 Korean news articles and 4 DART filings over the past seven days. Coverage peaked on Oct 21 with 4 articles.

Filing signals Insider buying 4 quarters of losses Screener

Orum Therapeutics quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩24m+479.1%−₩15.4bn₩63.4bn
Q1 2026₩0m-100.0%−₩18.1bn−₩15.3bn
Q4 2025 derived₩1m-77.5%−₩18.3bn−₩16.0bn
Q3 2025₩16m–−₩13.9bn−₩13.6bn
Q2 2025₩4m-74.3%−₩10.0bn−₩3.8bn
Q1 2025₩3m-80.9%−₩9.6bn−₩8.6bn
Q4 2024 derived₩2m–−₩7.9bn−₩10.9bn
Q3 2024 check units₩20.9bn–₩12.8bn₩14.4bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Orum Therapeutics top stories 2 weeks, by number of outlets

  1. 1
    오름테라퓨틱 이승주 대표, 주가 하락 속 1.7억 자사주 매입
    2 outlets · 3 articlesFirst report Oct 21 15:57 이데일리
  2. 2
    “내년 딜 1개 목표”…이승주 오름테라퓨틱 대표, 다음 승부수는?[화제의 바이오人]
    1 outlets · 2 articlesFirst report Oct 25 06:01 이데일리
  3. 3
    이승주 오름테라퓨틱 대표, 자사주 1만주 장내매수…1억7000만원 규모
    1 outlets · 1 articlesFirst report Oct 21 15:58 더바이오
  4. 4
    벌써 두 번 멈춘 신약 개발⋯오름테라퓨틱, 기술력 입증 '시험대'
    1 outlets · 1 articlesFirst report Oct 20 14:16 아이뉴스24
  5. 5
    오름테라퓨틱, 美 BD 전문가 이사회 복귀…BMS 이후 돌파구는
    1 outlets · 1 articlesFirst report Oct 23 11:31 이데일리
  6. 6
    오름테라퓨틱, 임시주총서 스톡옵션 10만8500주 가결
    1 outlets · 1 articlesFirst report Oct 25 10:59 비건뉴스

Latest Orum Therapeutics news Korean headlines